Document is current
Any future updates will be listed below
-
Authors
Wallblom, Karl https://orcid.org/0000-0003-0947-1450
Holmgren, Katja
Lundgren, Sigrid
Belfrage, Emma
Hoppe, Torborg
Hugerth, Matilda
Lindqvist, Anna-Karin
Sonkoly, Enikö
Schmidtchen, Artur
-
Funding
Funding for this research was provided by:
Lund University
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 21 November 2025
First Online: 2 December 2025
Declarations
:
: The study was run in accordance with the most recent update of the Declaration of Helsinki, and the International Council for Harmonization E6 Good Clinical Practice guideline, following approval by the national regulatory authority (Swedish Medical Products Agency) and national ethics committee, the Swedish Ethical Review Authority (Etikprövningsmyndigheten, application number 2022–00527-01, amendment number 2023–05051-02). Written informed consent was provided by all participants or by their parents/legal guardians (for those < 18 years of age) prior to their inclusion in the study.
: Not applicable.
: AS is a founder of and holds shares in in2cure AB, a parent company of Xinnate AB, which was the sponsor of the study and holds patents for TCP-25. MH and AKL are employed by Xinnate AB. The other authors declare that no conflict of interest exists.
